OneSpan Inc vs uniQure N.V. Ordinary Shares — how do they compare? OneSpan Inc trades at $17.52 (market cap $670.71M), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 2.2× OneSpan Inc's market cap, and OneSpan Inc pays a 2.86% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| OSPN | QURE | |
|---|---|---|
Market Cap | $670.71M | $1.48B |
Volume | 364,626 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $18.42 | $70.59 |
52-Week Low | $10.15 | $9.03 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $639.79M | $728.62M |
Dividend Yield | 2.86% | — |
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $18.20, up 1.96% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with a 73.58% gross margin and consistent earnings beats, though net cash flow turned negative in 2026. Recent product innovation with DigipassONE and positive analyst coverage support the current valuation.
The outlook remains positive given strong profitability metrics and analyst consensus, but investors should monitor cash flow trends and competitive pressures in the cybersecurity sector. The stock's current valuation appears reasonable with a P/E of 10.28, offering potential upside if execution continues.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →